U.S. markets close in 4 hours 5 minutes
  • S&P 500

    -23.82 (-0.63%)
  • Dow 30

    -169.35 (-0.55%)
  • Nasdaq

    -75.01 (-0.57%)
  • Russell 2000

    -33.75 (-1.57%)
  • Crude Oil

    -1.17 (-2.18%)
  • Gold

    -19.90 (-1.07%)
  • Silver

    -0.94 (-3.65%)

    -0.0054 (-0.45%)
  • 10-Yr Bond

    -0.0340 (-3.01%)

    -0.0086 (-0.63%)

    -0.0420 (-0.04%)

    -1,800.62 (-4.76%)
  • CMC Crypto 200

    -45.18 (-6.15%)
  • FTSE 100

    -66.25 (-0.97%)
  • Nikkei 225

    -179.08 (-0.62%)

The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Shanthi Rexaline

Biotech stocks see-sawed through the week ended Jan. 31 and ended the month lower overall. Big pharma earnings of the week were mostly disappointing.

Pfizer Inc. (NYSE: PFE) reported disappointing fourth-quarter earnings and Amgen, Inc. (NASDAQ: AMGN) guided 2020 below consensus, while Eli Lilly And Co (NYSE: LLY) managed to outperform expectations.

The week continued to see coronavirus-related spikes, with Cleveland BioLabs, Inc. (NASDAQ: CBLI), NanoViricides, Inc. (NASDAQ: NNVC), Vir Biotechnology, Inc. (NASDAQ: VIR) and Vaccinex, Inc. (NASDAQ: VCNX) among the stocks riding on the momentum.

Acceleron Pharma Inc (NASDAQ: XLRN) was one of the standout gainers of the week, thanks to a positive midstage clinical readout.

The much-anticipated FDA verdict on Aimmune Therapeutics Inc's (NASDAQ: AIMT) peanut allergy drug Palforzia came through in the week, with the regulatory agency greenlighting the drug.

Related Link: 7 Blockbuster Drugs Expected To Be Launched In 2020

View more earnings on IBB

Turning ahead to the unfolding week, the following are key catalysts that could create a ripple in the biotech space.


  • 2nd International Scientific & Clinical Congress on Spinal Muscular Atrophy: Feb. 5-7 in Paris, France

  • The European Association for Hemophilia and Allied Disorders, or EAHAD, 2020 Congress: Feb. 5-7 in Hague, Netherlands

  • ASCO-SITC Clinical Immuno-Oncology Symposium: Feb. 6-8 in Orlando, Florida

  • Angiogenesis, Exudation, and Degeneration 2020: Feb. 8 in Miami, Florida

Clinical Readouts

Forty Seven Inc (NASDAQ: FTSV) is due to present at the ASCO-SITC Symposium Phase 1b data for magrolimab + avelumab in ovarian cancer.

Jounce Therapeutics Inc (NASDAQ: JNCE) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors. (Feb. 6)

Catalyst Biosciences Inc (NASDAQ: CBIO) is scheduled to present at the EAHAD Congress Phase 2b data for dalcinonacog alfa in hemophilia B. (Feb. 7)

Kodiak Sciences Inc (NASDAQ: KOD) is due to present at the Angiogenesis, Exudation, and Degeneration 2020with Phase 1b data for KSI-301 in diabetic macular edema (Feb. 8)

Adverum Biotechnologies Inc (NASDAQ: ADVM) will present at the Angiogenesis, Exudation, and Degeneration 2020 with Phase 1 data for ADVM-022 in wet age-related macula degeneration. (Feb. 8)



  • Catalent Inc (NYSE: CTLT) (before the market open)

  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (after the close)


  • Zimmer Biomet Holdings Inc (NYSE: ZBH) (before the market open)

  • Haemonetics Corporation (NYSE: HAE) (before the market open)

  • BIO-TECHNE Corp (NASDAQ: TECH) (before the market open)

  • Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the close)

  • Gilead Sciences, Inc. (NASDAQ: GILD) (after the close)

  • Qiagen NV (NYSE: QGEN) (after the close)


  • Merck & Co., Inc. (NYSE: MRK) (before the market open)

  • Boston Scientific Corporation (NYSE: BSX) (before the market open)

  • Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) (after the close)

  • Cardiovascular Systems Inc (NASDAQ: CSII) (after the close)

  • Misonix Inc (NASDAQ: MSON) (after the close)

  • SurModics, Inc. (NASDAQ: SRDX) (after the close)


  • ABIOMED, Inc. (NASDAQ: ABMD) (before the market open)

  • Bristol-Myers Squibb Co (NYSE: BMY) (before the market open)

  • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (before the market open)

  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the market open)

  • Twist Bioscience Corp (NASDAQ: TWST) (after the close)

  • Anavex Life Sciences Corp (NASDAQ: AVXL) (after the close)

  • Pacific Biosciences of California (NASDAQ: PACB) (after the close)

  • Enanta Pharmaceuticals Inc (NASDAQ: ENTA) (after the close)

  • Myriad Genetics, Inc. (NASDAQ: MYGN) (after the close)

  • Seattle Genetics, Inc. (NASDAQ: SGEN) (after the close)

  • Natus Medical Inc (NASDAQ: NTUS) (after the close)

  • LeMaitre Vascular Inc (NASDAQ: LMAT) (after the close)

  • Ligand Pharmaceuticals Inc. (NASDAQ: LGND) (after the close)


  • AbbVie Inc (NYSE: ABBV (before the market open)

  • Meridian Bioscience, Inc. (NASDAQ: VIVO (before the market open)


Beam Therapeutics plans to offer 6.25 million shares in an IPO, with the offering expected to be priced between $15 and $17. The company, which is engaged in developing therapies based on single-base gene editing, has applied for listing its shares on the Nasdaq under the ticker symbol "BEAM."

Contract research organization PPD is planning a 60-million-share IPO to be priced in the range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol "PPD."


See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.